Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

14,408 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Subsequent malignant neoplasms in patients previously treated with anti-CD19 CAR T-cell therapy.
Melody M, Epperla N, Shouse G, Romancik J, Allen P, Moyo TK, Kenkre V, Ollila T, Fitzgerald L, Hess B, David K, Herr MM, Odetola O, Lin A, Moreira J, Ma S, Winter JN, Roy I, Stephens D, Danilov A, Shah NN, Barta SK, Cortese M, Cohen JB, Gordon LI, Karmali R. Melody M, et al. Among authors: ma s. Blood Adv. 2024 May 28;8(10):2327-2331. doi: 10.1182/bloodadvances.2024012573. Blood Adv. 2024. PMID: 38498727 Free PMC article. No abstract available.
Phase II study of alemtuzumab-rituximab therapy in previously untreated patients with chronic lymphocytic leukemia: short- and long-term outcomes.
Frankfurt O, Ma S, Gordon L, Winter JN, Horowitz JM, Rademaker A, Weitner BB, Peterson LC, Altman JK, Tallman MS, Petrich A, Rosen ST. Frankfurt O, et al. Among authors: ma s. Leuk Lymphoma. 2015 Feb;56(2):315-23. doi: 10.3109/10428194.2014.910654. Epub 2014 Jun 17. Leuk Lymphoma. 2015. PMID: 24707943 Clinical Trial.
Ibrutinib, a Bruton's tyrosine kinase inhibitor used for treatment of lymphoproliferative disorders, eliminates both aeroallergen skin test and basophil activation test reactivity.
Regan JA, Cao Y, Dispenza MC, Ma S, Gordon LI, Petrich AM, Bochner BS. Regan JA, et al. Among authors: ma s. J Allergy Clin Immunol. 2017 Sep;140(3):875-879.e1. doi: 10.1016/j.jaci.2017.03.013. Epub 2017 Apr 4. J Allergy Clin Immunol. 2017. PMID: 28389390 Free PMC article. No abstract available.
A phase I/II trial of brentuximab vedotin plus rituximab as frontline therapy for patients with immunosuppression-associated CD30+ and/or EBV + lymphomas.
Pearse WB, Petrich AM, Gordon LI, Karmali R, Winter JN, Ma S, Kaplan JB, Behdad A, Klein A, Jovanovic B, Helenowski I, Smith SM, Evens AM, Pro B. Pearse WB, et al. Among authors: ma s. Leuk Lymphoma. 2021 Dec;62(14):3493-3500. doi: 10.1080/10428194.2021.1957867. Epub 2021 Aug 2. Leuk Lymphoma. 2021. PMID: 34338127 Clinical Trial.
Peri-CAR-T practice patterns and survival predictors for all CAR-T patients and post-CAR-T failure in aggressive B-NHL.
Zurko J, Nizamuddin I, Epperla N, David K, Cohen JB, Moyo TK, Ollila T, Hess B, Roy I, Ferdman R, Liu J, Chowdhury SM, Romancik J, Bhansali RS, Harris EI, Sorrell M, Masel R, Kittai AS, Denlinger N, Sigmund AM, Fitzgerald L, Galvez C, Ma S, Winter J, Pro B, Gordon LI, Danilov A, Stephens D, Shah NN, Kenkre V, Barta SK, Torka P, Shouse G, Karmali R. Zurko J, et al. Among authors: ma s. Blood Adv. 2023 Jun 27;7(12):2657-2669. doi: 10.1182/bloodadvances.2022008240. Blood Adv. 2023. PMID: 36094847 Free PMC article.
Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL).
Odetola O, Ma S. Odetola O, et al. Among authors: ma s. Curr Hematol Malig Rep. 2023 Oct;18(5):130-143. doi: 10.1007/s11899-023-00700-z. Epub 2023 Jun 6. Curr Hematol Malig Rep. 2023. PMID: 37278884 Free PMC article. Review.
14,408 results
You have reached the last available page of results. Please see the User Guide for more information.